10x Genomics and Cleveland Clinic Collaborate to Advance Research in Diagnostic Applications of Single Cell and Spatial Technologies in Patients with Bladder Cancer
Collaboration aims to identify biomarkers predictive of antibody-drug conjugate (ADC) treatment response using 10x’s single cell and spatial platforms
Excerpt from the Press Release:
PLEASANTON, Calif., June 17, 2026 /PRNewswire/ — 10x Genomics, Inc. (Nasdaq: TXG), the life science technology leader focused on accelerating science and advancing human health, today announced a research collaboration with Cleveland Clinic, a nonprofit multispecialty academic medical center that integrates clinical care with research and education, to advance research in novel diagnostics for bladder cancer.
This collaboration is part of 10x’s broader efforts to partner with leading research institutions to generate the evidence needed to support the future development of diagnostic applications across oncology and other disease areas.
Through this multi-year collaboration, the study intends to initially examine tumor samples from patients with advanced bladder cancer undergoing emerging therapeutic regimens using 10x’s Flex Apex and Xenium platforms, with the goal of expanding to the recently announced Atera platform. The research aims to identify clinically relevant biomarkers that may help predict bladder cancer patient response to treatment and support future diagnostic development across tumor types.
Click the button below to read the entire Press Release:
Discover What Sets TrialStat Apart From Ordinary EDC Platforms
Click the image or button below to explore our eClinical Suite Platform and discover what sets TrialStat apart from competing EDC platforms.
Request Your Demo Today!
From rapid database build through database lock, we deliver consistent quality on-time and on-budget. Ready to upgrade your eClinical toolkit?